Major histocompatibility complex class II binding characteristics of peptoid-peptide hybrids.
暂无分享,去创建一个
M. Wauben | R. Liskamp | J. Kruijtzer | Rob M J Liskamp | Ed E Moret | Marca H M Wauben | E. Moret | Ellen C de Haan | Mayken C Grosfeld-Stulemeyer | John A W Kruijtzer | E. D. de Haan | M. Grosfeld-Stulemeyer
[1] D. Wiley,et al. The Crystal Structure of a Pyrrolinone−Peptide Hybrid Ligand Bound to the Human Class II MHC Protein HLA-DR1 , 2000 .
[2] A. Vandenbark,et al. Selectin of encephalitogenic rat T‐Lymphocyte clones recognizing an immunodominant epitope on myelin basic protein , 1989, Journal of neuroscience research.
[3] R Crowther,et al. Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures. , 2000, Journal of medicinal chemistry.
[4] S. Ceman,et al. Individual hydrogen bonds play a critical role in MHC class II:peptide interactions: implications for the dynamic aspects of class II trafficking and DM‐mediated peptide exchange , 1999, Immunological reviews.
[5] G. Jung,et al. Cutting edge: N-hydroxy peptides: a new class of TCR antagonists. , 1999, Journal of immunology.
[6] R. Campbell,et al. Design and Synthesis of a Competent Pyrrolinone−Peptide Hybrid Ligand for the Class II Major Histocompatibility Complex Protein HLA-DR1 , 1999 .
[7] J. Guenot,et al. Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules , 1999, Nature Biotechnology.
[8] P. Kourilsky,et al. Role of peptide backbone in T cell recognition. , 1999, Journal of immunology.
[9] Don C. Wiley,et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide , 1994, Nature.
[10] A. Sant,et al. Cutting edge: a single, essential hydrogen bond controls the stability of peptide-MHC class II complexes. , 1999, Journal of immunology.
[11] D. Kirschmann,et al. A peptidomimetic that specifically inhibits human leukocyte antigen DRB1*0401-restricted T cell proliferation. , 1997, The Journal of pharmacology and experimental therapeutics.